Consequences of delayed treatment effects on analysis of time-to-event endpoints

被引:50
|
作者
Fine, Gil D. [1 ]
机构
[1] SuperGen Inc, Dublin, CA 94568 USA
来源
DRUG INFORMATION JOURNAL | 2007年 / 41卷 / 04期
关键词
survival analysis; log rank; weighted test; power; pancreatic cancer;
D O I
10.1177/009286150704100412
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The assumption of proportional hazard ratios is implicit in certain analyses of time-to-event endpoints such as Cox regression. Other statistical analyses, such as the nonparametric log-rank test, possess some desirable properties only under the proportional hazards model. Data models for delayed effects of treatment on time-to-event endpoints such as survival violate the proportional hazards assumption. Fleming and Harrington's G(rho,gamma) class of weighted log-rank tests, a new option in SAS 9.1, is appropriate to test against a broad range of alternative hypotheses, including delayed treatment effects. A model for delayed treatment effects is proposed, and it is demonstrated that weighted log-rank tests are more powerful under this model than the standard unweighted log-rank test.
引用
收藏
页码:535 / 539
页数:5
相关论文
共 50 条
  • [1] Consequences of Delayed Treatment Effects on Analysis of Time-to-Event Endpoints
    Gil D. Fine
    [J]. Drug information journal : DIJ / Drug Information Association, 2007, 41 : 535 - 539
  • [2] Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints
    Beisel, Christina
    Benner, Axel
    Kunz, Christina
    Kopp-Schneider, Annette
    [J]. BIOMETRICAL JOURNAL, 2017, 59 (03) : 511 - 530
  • [3] Adjusted estimates for time-to-event endpoints
    Storer, Barry E.
    Gooley, Ted A.
    Jones, Michael P.
    [J]. LIFETIME DATA ANALYSIS, 2008, 14 (04) : 484 - 495
  • [4] Adjusted estimates for time-to-event endpoints
    Barry E. Storer
    Ted A. Gooley
    Michael P. Jones
    [J]. Lifetime Data Analysis, 2008, 14 : 484 - 495
  • [5] Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond
    Rufibach, Kaspar
    [J]. PHARMACEUTICAL STATISTICS, 2019, 18 (02) : 145 - 165
  • [6] Analysis of composite time-to-event endpoints in cardiovascular outcome trials
    Marceau West, Rachel
    Golm, Gregory
    Mehrotra, Devan, V
    [J]. CLINICAL TRIALS, 2024,
  • [7] Time-to-Event Endpoints in Imaging Biomarker Studies
    Chen, Ruizhe
    Wang, Hao
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2024,
  • [8] Sensitivity to censored-at-random assumption in the analysis of time-to-event endpoints
    Lipkovich, Ilya
    Ratitch, Bohdana
    O'Kelly, Michael
    [J]. PHARMACEUTICAL STATISTICS, 2016, 15 (03) : 216 - 229
  • [9] Longitudinal mediation analysis of time-to-event endpoints in the presence of competing risks
    Tat-Thang Vo
    Hilary Davies-Kershaw
    Ruth Hackett
    Stijn Vansteelandt
    [J]. Lifetime Data Analysis, 2022, 28 : 380 - 400
  • [10] Meta-analysis of clinical trials with competing time-to-event endpoints
    Meddis, Alessandra
    Latouche, Aurelien
    Zhou, Bingqing
    Michiels, Stefan
    Fine, Jason
    [J]. BIOMETRICAL JOURNAL, 2020, 62 (03) : 712 - 723